奥曲肽联合经动脉插管化疗栓塞治疗伴肝硬化肝细胞癌_临床医学论文.docVIP

奥曲肽联合经动脉插管化疗栓塞治疗伴肝硬化肝细胞癌_临床医学论文 奥曲肽联合经动脉插管化疗栓塞治疗伴肝硬化肝细胞癌_临床医学论文 【摘要】 　　目的 评价奥曲肽联合经动脉插管化疗栓塞（TACE）治疗伴肝硬化肝细胞癌的临床效果。方法 选择Child-Pugh评分A或B级伴肝硬化肝细胞癌患者共55例。实验组24例，行TACE术后第1天开始使用奥曲肽0.2mg皮下注射，每天2次。对照组31例，接受TACE治疗。每3个月进行1次评价。对两组6个月及1、2、3年的生存率进行比较。结果 两组均无CR，实验组中16例PR，有效率为66.67%。对照组中11例PR，有效率为35.48%。两组有效率差异有显著性(0.05)。实验组3年生存率为45.83%，而对照组3年生存率为19.35%。两组3年生存率差异有显著性（0.05）。实验组中位生存期为31个月，对照组中位生存期为20个月。实验组中位TTP为9个月，对照组为6个月。奥曲肽副作用主要为轻度腹泻。结论 奥曲肽联合TACE治疗伴肝硬化肝细胞癌有明确的效果。 【关键词】 奥曲肽；肝硬化；肝细胞癌；化学栓塞，治疗性 Abstract: Objective This article is to evaluate the effects of octreotide in combination with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma complicated with liver cirrhosis. Methods Fifty-five consecutive patients in Child-Pugh classification A and B were admitted into the 3-year trial. Twenty-four patients in the octreotide group received octreotide 0.2mg IH twice a day following the treatment of TACE on day 1. Thirty-one patients received TACE alone were enrolled into the control group. The efficacy were assessed once every 3 months. A comparison of the 6-month、1-year、2-year and 3-year survival rate between the two groups were performed. Results No complete response was got in both groups. In the octreotide group, partial response (PR) was got in 16 (66.67%) of the 24 patients, whereas in the control group, PR was achieved in 11 (35.48%) of the 31 patients. There was statistical significant difference in response rate between the two groups (0.05). The 3-year overall survival rate of the octreotide group and the control group were 45.83% and 19.35%, respectively. There was statistical significant difference in 3-year overall survival rate between the two groups (0.05). The overall survival rate of the octreotide group was significantly higher than that of the control group (p lt; 0.05). The median survival of the octreotide group and the control group were 31 months and 20 months, respectively. The aliment development in the octreotide group was 9 months vs 6 m